Adam and Dave Schechter a case of nepotism?

Discussion in 'Merck' started by Anonymous, Sep 4, 2013 at 11:11 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest


    I am sure Dave will be promoted. But what has he done?
     

  2. anonymous

    anonymous Guest

    It is not your concern what happens with Dave, your only concern is to deliver deli until Dec 31 and then bye bye! Scum sucker!
     
  3. anonymous

    anonymous Guest

    Dave is fabulous we all love Dave and he is smart and wonderful.

    We want no trouble with him nor his big brother.
     
  4. anonymous

    anonymous Guest

    DCO ?
     
  5. anonymous

    anonymous Guest

    Guess it is Country Director Israel
     
  6. anonymous

    anonymous Guest

    Hey my favorite Turkeys Adam and Dave, enjoyed their gobble gobble day.
     
  7. anonymous

    anonymous Guest

    Dave seriously you should stop taking this personally and be mature about the intent behind these anonymous posts. Obviously this is a sensitive topic which we cannot openly discuss.

    You have to accept that you having been getting promotions, raises, stock options and opportunity as a preferential treatment because you are the brother of Adam, who is in charge of USHH. Your peers agree unanimously that you are condescending in your judgement, lazy, lack insights, intimidating, and incompetent to be in the current position.

    Frankly, you are denying opportunities to other more qualified candidates.

    That is what makes this a case of nepotism and that it is so unfair to your peers, your managers and a indeed a conflict which needs to be resolved. So please help further embarrassment to your brother and the company.

    As a resolution, consider applying for a job in another company or becoming a handy man on Adam's Farm.

    Surely by taking this action you will qualify for a good exit package.
     
  8. anonymous

    anonymous Guest

    They are the chosen and will lead Merck through the Red Sea and save the company from the useless.
     
  9. anonymous

    anonymous Guest

    I know and work with Dave and he really sucks. Surrounded by a circle of cronies preventing progress.
     
  10. anonymous

    anonymous Guest

    Nepotisim is easy to prove with facts and background search.

    To associate a conflict and preferential treatment for Dave and his cronies, get someone in HR to examine Dave's promotional raises, ratings and compensation over the past 10 years and do the same for all his managers.

    With confidence the evidence will show both Dave and manager's over time received significant inflation in their salary increases and overall compensation.

    That is the travesty!
     
  11. anonymous

    anonymous Guest

    These are two ruthless brothers with one agenda to self serve.
     
  12. anonymous

    anonymous Guest

    Totally agree. Recently, Dave shared feedback on my work even though he had no clue on what I accomplished. It sucks when you have an ass like that. I too have family but not like his brother.
     
  13. anonymous

    anonymous Guest

    the turds must go.
     
  14. anonymous

    anonymous Guest

    These are two ruthless cunning and selfish brothers.
     
  15. anonymous

    anonymous Guest

    Succession planning made so easy for brother Dave and HR specialist. Adam is ready to approve Dave's next job or else.
     
  16. anonymous

    anonymous Guest

    Brother Dave is doing a terrific job I gave him all the necessary resources from his peers who were not performing....it worked. Keep it up brother.

    Merck has been spending heavily on marketing DPP-4 inhibitor Januvia, and thus far it's been working. Sales of the drug were up 10% in the third quarter from the prior-year period, and 17% on an operational basis. But the emergence of SGLT-2 inhibitors creates a challenge.
     
  17. anonymous

    anonymous Guest

    So finally the bubbles bursts on Januvia franchise, the brother to brother strategy crashes. So time to go into the 'Spin Zone'.
    "Sales of Januvia and a related drug called Janumet, the company's biggest franchise, fell 12 percent to $1.45 billion. Merck said their tumble was due in large part to timing of customer purchases in the third quarter. Competition from a growing number of other oral diabetes treatments also hurt sales".
     
  18. anonymous

    anonymous Guest

    Finally Dave and his Januvia team woke up and have launched newly focused DTC ads to reverse and stop SGLT-2 share gains.
     
  19. anonymous

    anonymous Guest

    Brothers are dishonest and cunning contriving scoundrels not to be trusted.
     
  20. anonymous

    anonymous Guest

    Merck could save $10 Million a year by letting go of these two brothers and hiring 50 mangers who understand people, health care and implementation to turn this company around. Such a pathetic place to work.